Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis.
about
Role of insulin in the type 2 diabetes therapy: past, present and futureIntensive glucose control versus conventional glucose control for type 1 diabetes mellitusThe Rationale for Insulin Therapy in Alzheimer's DiseaseCardiovascular effects of basal insulinsThe evolution of insulin glargine and its continuing contribution to diabetes careModern basal insulin analogs: An incomplete storyrDNA insulin glargine U300 - a critical appraisalTherapeutics of diabetes mellitus: focus on insulin analogues and insulin pumps.Health economic evaluations comparing insulin glargine with NPH insulin in patients with type 1 diabetes: a systematic review.Home use of closed-loop insulin delivery for overnight glucose control in adults with type 1 diabetes: a 4-week, multicentre, randomised crossover studyClinical experience with insulin glargine in type 1 diabetes.A prospective randomised cross-over study of the effect of insulin analogues and human insulin on the frequency of severe hypoglycaemia in patients with type 1 diabetes and recurrent hypoglycaemia (the HypoAna trial): study rationale and design.Safety, effectiveness, and cost effectiveness of long acting versus intermediate acting insulin for patients with type 1 diabetes: systematic review and network meta-analysis.Efficacy and safety of insulin degludec given as part of basal-bolus treatment with mealtime insulin aspart in type 1 diabetes: a 26-week randomized, open-label, treat-to-target non-inferiority trial.Modern insulins, old paradigms and pragmatism: choosing wisely when deciding how to treat type 1 diabetes.Evidence-informed clinical practice recommendations for treatment of type 1 diabetes complicated by problematic hypoglycemia.Results of glycated hemoglobin during treatment with insulin analogues dispensed in the public health system of Federal District in Brazil.Prescribing of Antidiabetic Medicines before, during and after Pregnancy: A Study in Seven European RegionsBudget Impact of Long-Acting Insulin Analogues: The Case in BrazilDesign and rationale of a large, international, prospective cohort study to evaluate the occurrence of malformations and perinatal/neonatal death using insulin detemir in pregnant women with diabetes in comparison with other long-acting insulinsInsulin therapy and cancer in type 2 diabetes.Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patientsContemporary rates of severe hypoglycaemia in youth with type 1 diabetes: variability by insulin regimenA retrospective study comparing neutral protamine hagedorn insulin with glargine as basal therapy in prednisone-associated diabetes mellitus in hospitalized patientsApproach to assessing the economic impact of insulin-related hypoglycaemia using the novel Local Impact of Hypoglycaemia ToolCerebral blood flow and glucose metabolism in appetite-related brain regions in type 1 diabetic patients after treatment with insulin detemir and NPH insulin: a randomized controlled crossover trial.Hypoglycaemia during pregnancy in women with Type 1 diabetes.Intensifying insulin treatment: options, practical issues, and the role of the nurse practitioner.The need for better insulin therapy.Pharmacologic agents for type 2 diabetes therapy and regulation of adipogenesis.Physiologic and weight-focused treatment strategies for managing type 2 diabetes mellitus: the metformin, glucagon-like peptide-1 receptor agonist, and insulin (MGI) approach.Safety, effectiveness, and cost of long-acting versus intermediate-acting insulin for type 1 diabetes: protocol for a systematic review and network meta-analysis.Management of type 1 diabetes in children and adolescents.The latest pharmacotherapy options for type 1 diabetes.Insulin glargine in a Brazilian state: should the government disinvest? An assessment based on a systematic review.An update on the pharmacotherapy options for pediatric diabetes.Comparing dosing of basal insulin analogues detemir and glargine: is it really unit-per-unit and dose-per-dose?Influence of the type of Basal insulin and other variables on clinical outcomes in children with newly diagnosed type 1 diabetes.Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial.The past, present, and future of basal insulins.
P2860
Q22241148-60834E5F-73FC-4F36-944C-D524FD9A3B2EQ24200376-5857BD7A-EF01-4D28-8E19-0D508B663853Q26744834-5B8EB37D-1E56-40C1-931D-8D0E01140C18Q26800249-3228C10A-AB0A-4FF5-9B3A-737E2DBAED5AQ26999454-D47F8AD0-8900-460C-B272-E38EF93E999EQ27015047-309FB62D-1938-45B6-BB00-DF1590EB7964Q28077366-AA15B5F1-8D35-4B5A-BA5A-397168B4A75FQ33879565-2F48F9A8-0AAA-4BB9-829D-18E0F6DC47FFQ34042148-DCAFBED9-F5E8-4595-B8FC-CC47F76F177BQ34194737-42188208-BEB1-46DF-A509-85014760E47AQ34296834-94505193-B799-4EC1-8233-D035913B39FEQ34315270-132CB2BD-C1D1-4C4B-94B3-CD08929FF714Q34349437-FC46D780-54A1-478D-94B7-A2C79E5C4F11Q34543035-C0B671D1-0456-4D1D-8334-BF97203C6AA9Q35590648-D89693BB-EC5C-4093-A264-609DF8716897Q35630711-115B77FF-C105-49ED-ACA4-6B2952B5D9F9Q35964744-3A29F7AF-F1EC-4FAB-BAF6-B52FE76D84B1Q36021430-B417A4B9-6608-4339-8DC0-1751910A36C5Q36209792-A522DE51-6B85-493E-81A3-C2E2AB658F6EQ36253086-63FA0EB0-4686-408C-8397-C0868DA6FF50Q36417868-83795095-21D1-4763-85A8-7E7FD831C3E0Q36637960-CF232353-7361-40F6-B62A-63718989AE56Q36683323-E7329635-C849-468C-B577-57A2522A2C1AQ36899667-5D09C8F4-07F7-477F-93E2-07AB4F01D1F3Q37269489-BB15D359-67B1-4A5B-967E-CC9975F2E7E1Q37331162-2B403546-9BEE-41C9-B0B8-7720D9D5C361Q37982107-998B16CF-AAFE-40BE-80A4-D606249CABC4Q38008006-1CAFEDC7-ADC5-48B2-A780-8BFB6185FE3DQ38085331-9E71A545-170D-4CD2-8D26-7A990AAE84D6Q38110890-C32517EF-E6CC-4FD4-8801-7E072D45FEB9Q38113095-FCBCC4E8-2803-41C0-B8C8-6A4B1266BAF6Q38135925-9E37A28F-3A36-430D-A342-38AADB083108Q38151474-584F7E96-CA62-43D8-8361-845467115CFFQ38167387-358C9603-68D1-4625-866E-EFD89D31F297Q38175354-629AF721-3FF6-4623-BF7D-79CD50DE3C3EQ38175521-CAA54D03-513C-4700-9208-4CDAA99E8A67Q38176344-3BEF110B-073E-4127-9550-0D6C3C30CB09Q38198025-E9C0D357-5F80-4D2D-B5D2-027C6D485500Q38374620-5B14AA84-7FAF-44F7-B037-771BA110CBF0Q38618376-5BF14E94-E1AE-4CCD-8598-2FBFEC14C558
P2860
Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis.
@en
Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis.
@nl
type
label
Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis.
@en
Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis.
@nl
prefLabel
Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis.
@en
Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis.
@nl
P2093
P921
P1476
Long-acting insulin analogues vs. NPH human insulin in type 1 diabetes. A meta-analysis.
@en
P2093
E Mannucci
N Marchionni
P304
P356
10.1111/J.1463-1326.2008.00976.X
P577
2009-04-01T00:00:00Z